Antoni Ribas

Title(s)Professor, Medicine
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)Professor, Surgery

    Title(s)Professor, Molecular and Medical Pharmacology


    Collapse Research 
    Collapse Research Activities and Funding
    Combination Therapies to Defeat Melanoma Resistance
    NIH P01CA244118Sep 11, 2020 - Jun 30, 2025
    Role: Principal Investigator
    Immuno-Targeted Therapy for Melanoma
    NIH R35CA197633Sep 9, 2015 - Aug 31, 2022
    Role: Principal Investigator
    Nanosystems Biology Cancer Center
    NIH U54CA199090Sep 1, 2015 - Jul 31, 2021
    Role: Co-Principal Investigator
    Response and Acquired Resistance to PD-1 Blockade
    NIH R01CA199205Jul 1, 2015 - Jun 30, 2016
    Role: Principal Investigator
    Overcoming BRAF-inhibitor Resistance in Melanoma
    NIH P01CA168585Jul 1, 2013 - Jun 30, 2019
    Role: Principal Investigator
    Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)
    NIH R01CA170689Sep 1, 2012 - Jun 30, 2016
    Role: Co-Principal Investigator
    AFP-Based Immunotherapy for Hepatocellular Carcinoma
    NIH K23CA093376Sep 1, 2002 - Aug 31, 2007
    Role: Principal Investigator
    Academic Training in Medical Oncology
    NIH T32CA009297Jun 1, 1979 - Jun 30, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A Spatial Omnibus Test (SPOT) for Spatial Proteomic Data. bioRxiv. 2024 Mar 13. Samorodnitsky S, Campbell K, Ribas A, Wu MC. PMID: 38559053; PMCID: PMC10979932.
      View in: PubMed   Mentions:
    2. Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer. Cell Rep. 2024 Feb 29; 43(3):113872. Chen DG, Xie J, Choi J, Ng RH, Zhang R, Li S, Edmark R, Zheng H, Solomon B, Campbell KM, Medina E, Ribas A, Khatri P, Lanier LL, Mease PJ, Goldman JD, Su Y, Heath JR. PMID: 38427562.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nat Commun. 2024 Feb 09; 15(1):1244. Jilani S, Saco JD, Mugarza E, Pujol-Morcillo A, Chokry J, Ng C, Abril-Rodriguez G, Berger-Manerio D, Pant A, Hu J, Gupta R, Vega-Crespo A, Baselga-Carretero I, Chen JM, Shin DS, Scumpia P, Radu RA, Chen Y, Ribas A, Puig-Saus C. PMID: 38336975; PMCID: PMC10858182.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    4. Correction: ERK mediates interferon gamma-induced melanoma cell death. Mol Cancer. 2024 Feb 05; 23(1):29. Champhekar A, Heymans R, Saco J, Font GT, Gonzalez C, Gao A, Pham J, Lee J, Maryoung R, Medina E, Campbell KM, Karin D, Austin D, Damioseaux R, Ribas A. PMID: 38317137; PMCID: PMC10840292.
      View in: PubMed   Mentions:    Fields:    
    5. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 Jan 23. Algazi AP, Moon J, Lao CD, Chmielowski B, Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, Latkovic-Taber M, Lomeli SH, Gufford BT, Scumpia PO, Lo RS, Othus M, Ribas A. PMID: 38261444.
      View in: PubMed   Mentions:    Fields:    
    6. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024 Mar; 199:113530. Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. PMID: 38295556.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer. JAAD Int. 2024 Jun; 15:62-68. Katz S, Ciuba D, Ribas A, Shelach N, Zelinger G, Barrow B, Corn BW. PMID: 38405632; PMCID: PMC10891318.
      View in: PubMed   Mentions:
    8. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2023 Dec 15; 133(24). Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ. PMID: 38099495; PMCID: PMC10721136.
      View in: PubMed   Mentions:    Fields:    
    9. Antitumor Immune Responses in B2M-Deficient Cancers. Cancer Immunol Res. 2023 12 01; 11(12):1642-1655. Torrejon DY, Galvez M, Abril-Rodriguez G, Campbell KM, Medina E, Vega-Crespo A, Kalbasi A, Comin-Anduix B, Ribas A. PMID: 37801341; PMCID: PMC10842455.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    10. Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy. Cancer Immunol Res. 2023 12 01; 11(12):1589-1597. Nowicki TS, Peters CW, Quiros C, Kidd CK, Kawakami M, Klomhaus AM, Baselga-Carretero I, Kaplan-Lefko P, Macabali MH, Perez Garcilazo I, Berent-Maoz B, Comin-Anduix B, Ribas A. PMID: 37871333; PMCID: PMC10702871.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    11. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nat Rev Drug Discov. 2023 12; 22(12):996-1017. Klebanoff CA, Chandran SS, Baker BM, Quezada SA, Ribas A. PMID: 37891435; PMCID: PMC10947610.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    12. An NKG2A biased immune response confers protection for infection, autoimmune disease, and cancer. Res Sq. 2023 Oct 16. Heath J, Chen D, Xie J, Choi J, Ng R, Zhang R, Li S, Edmark R, Zheng H, Solomon B, Campbell K, Medina E, Ribas A, Khatri P, Lanier L, Mease P, Goldman J, Su Y. PMID: 37886475; PMCID: PMC10602172.
      View in: PubMed   Mentions:
    13. ERK mediates interferon gamma-induced melanoma cell death. Mol Cancer. 2023 10 06; 22(1):165. Champhekar A, Heymans R, Saco J, Turon Font G, Gonzalez C, Gao A, Pham J, Lee J, Maryoung R, Medina E, Campbell KM, Karin D, Austin D, Damioseaux R, Ribas A. PMID: 37803324; PMCID: PMC10557262.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    14. Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell. 2023 09 11; 41(9):1680-1688.e2. Topp BG, Channavazzala M, Mayawala K, De Alwis DP, Rubin E, Snyder A, Wolchok JD, Ribas A. PMID: 37699333.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer. Cancer Res Commun. 2023 08; 3(8):1628-1637. Nguyen VP, Campbell KM, Nowicki TS, Elumalai N, Medina E, Baselga-Carretero I, DiNome ML, Chang HR, Oseguera DK, Ribas A, Glaspy JA. PMID: 37621406; PMCID: PMC10445661.
      View in: PubMed   Mentions: 2  Translation:HumansCTClinical Trials
    16. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023 09; 29(9):2278-2285. VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. PMID: 37592104; PMCID: PMC10708907.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    17. Rigorous benchmarking of T-cell receptor repertoire profiling methods for cancer RNA sequencing. Brief Bioinform. 2023 07 20; 24(4). Peng K, Nowicki TS, Campbell K, Vahed M, Peng D, Meng Y, Nagareddy A, Huang YN, Karlsberg A, Miller Z, Brito J, Nadel B, Pak VM, Abedalthagafi MS, Burkhardt AM, Alachkar H, Ribas A, Mangul S. PMID: 37291798; PMCID: PMC10359085.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    18. Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. J Clin Oncol. 2023 08 20; 41(24):3998-4003. Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV. PMID: 37348035.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    19. Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. J Immunother Cancer. 2023 06; 11(6). Clifton GT, Rothenberg M, Ascierto PA, Begley G, Cecchini M, Eder JP, Ghiringhelli F, Italiano A, Kochetkova M, Li R, Mechta-Grigoriou F, Pai SI, Provenzano P, Puré E, Ribas A, Schalper KA, Fridman WH. PMID: 37290925; PMCID: PMC10254706.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    20. Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. Sci Transl Med. 2023 05 17; 15(696):eadg0675. Lechner MG, Zhou Z, Hoang AT, Huang N, Ortega J, Scott LN, Chen HC, Patel AY, Yakhshi-Tafti R, Kim K, Hugo W, Famini P, Drakaki A, Ribas A, Angell TE, Su MA. PMID: 37196065; PMCID: PMC10227862.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    21. IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. Proc Natl Acad Sci U S A. 2023 05 23; 120(21):e2221116120. Pan Y, Phillips JW, Zhang BD, Noguchi M, Kutschera E, McLaughlin J, Nesterenko PA, Mao Z, Bangayan NJ, Wang R, Tran W, Yang HT, Wang Y, Xu Y, Obusan MB, Cheng D, Lee AH, Kadash-Edmondson KE, Champhekar A, Puig-Saus C, Ribas A, Prins RM, Seet CS, Crooks GM, Witte ON, Xing Y. PMID: 37192158; PMCID: PMC10214192.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    22. Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade. J Immunother Cancer. 2023 05; 11(5). Frankiw L, Singh A, Peters C, Comin-Anduix B, Berent-Maoz B, Macabali M, Shammaie K, Quiros C, Kaplan-Lefko P, Baselga Carretero I, Ribas A, Nowicki TS. PMID: 37156551; PMCID: PMC10173990.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. Cancers (Basel). 2023 Apr 29; 15(9). Eljilany I, Noor A, Paravathaneni M, Yassine I, Lee SJ, Othus M, Moon J, Kirkwood JM, Sondak VK, Ribas A, Grossmann KF, Tarhini AA. PMID: 37174027; PMCID: PMC10177189.
      View in: PubMed   Mentions:
    24. Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell. 2023 04 10; 41(4):791-806.e4. Campbell KM, Amouzgar M, Pfeiffer SM, Howes TR, Medina E, Travers M, Steiner G, Weber JS, Wolchok JD, Larkin J, Hodi FS, Boffo S, Salvador L, Tenney D, Tang T, Thompson MA, Spencer CN, Wells DK, Ribas A. PMID: 37037616; PMCID: PMC10187051.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. Computational prediction of MHC anchor locations guides neoantigen identification and prioritization. Sci Immunol. 2023 04 14; 8(82):eabg2200. Xia H, McMichael J, Becker-Hapak M, Onyeador OC, Buchli R, McClain E, Pence P, Supabphol S, Richters MM, Basu A, Ramirez CA, Puig-Saus C, Cotto KC, Freshour SL, Hundal J, Kiwala S, Goedegebuure SP, Johanns TM, Dunn GP, Ribas A, Miller CA, Gillanders WE, Fehniger TA, Griffith OL, Griffith M. PMID: 37027480; PMCID: PMC10450883.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    26. Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma. Cancer Discov. 2023 04 03; 13(4):880-909. Dharanipragada P, Zhang X, Liu S, Lomeli SH, Hong A, Wang Y, Yang Z, Lo KZ, Vega-Crespo A, Ribas A, Moschos SJ, Moriceau G, Lo RS. PMID: 36700848; PMCID: PMC10068459.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    27. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature. 2023 03; 615(7953):697-704. Puig-Saus C, Sennino B, Peng S, Wang CL, Pan Z, Yuen B, Purandare B, An D, Quach BB, Nguyen D, Xia H, Jilani S, Shao K, McHugh C, Greer J, Peabody P, Nayak S, Hoover J, Said S, Jacoby K, Dalmas O, Foy SP, Conroy A, Yi MC, Shieh C, Lu W, Heeringa K, Ma Y, Chizari S, Pilling MJ, Ting M, Tunuguntla R, Sandoval S, Moot R, Hunter T, Zhao S, Saco JD, Perez-Garcilazo I, Medina E, Vega-Crespo A, Baselga-Carretero I, Abril-Rodriguez G, Cherry G, Wong DJ, Hundal J, Chmielowski B, Speiser DE, Bethune MT, Bao XR, Gros A, Griffith OL, Griffith M, Heath JR, Franzusoff A, Mandl SJ, Ribas A. PMID: 36890230; PMCID: PMC10441586.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    28. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 Mar 02; 388(9):813-823. Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. PMID: 36856617; PMCID: PMC10410527.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCTClinical Trials
    29. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov. 2023 03 01; 13(3):580-597. Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY. PMID: 36416874; PMCID: PMC9992104.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    30. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncol. 2023 02 01; 9(2):251-260. Unger JM, Darke A, Othus M, Truong TG, Khushalani N, Kendra K, Lewis KD, Faller B, Funchain P, Buchbinder EI, Tarhini AA, Kirkwood JM, Sharon E, Sondak V, Guild SR, Grossmann K, Ribas A, Patel SP. PMID: 36416836; PMCID: PMC9685550.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    31. Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens. Nat Genet. 2023 01; 55(1):19-25. Wang Y, Fan JL, Melms JC, Amin AD, Georgis Y, Barrera I, Ho P, Tagore S, Abril-Rodríguez G, He S, Jin Y, Biermann J, Hofree M, Caprio L, Berhe S, Khan SA, Henick BS, Ribas A, Macosko EZ, Chen F, Taylor AM, Schwartz GK, Carvajal RD, Azizi E, Izar B. PMID: 36624340; PMCID: PMC10155259.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    32. Publisher Correction: Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature. 2022 Dec; 612(7938):E10. Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, Song D, Rommel PC, Radaelli E, Young RM, Leonard WJ, Ribas A, June CH, Garcia KC. PMID: 36380037; PMCID: PMC9712099.
      View in: PubMed   Mentions: 1     Fields:    
    33. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023 03; 615(7953):687-696. Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AHC, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ. PMID: 36356599; PMCID: PMC9768791.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCellsCTClinical Trials
    34. Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockade. Cancer Res Commun. 2022 10; 2(10):1214-1228. Abril-Rodríguez G, Torrejon DY, Karin D, Campbell KM, Medina E, Saco JD, Galvez M, Champhekar AS, Perez-Garcilazo I, Baselga-Carretero I, Singh J, Comin-Anduix B, Puig-Saus C, Ribas A. PMID: 36588582; PMCID: PMC9799984.
      View in: PubMed   Mentions: 2  Translation:AnimalsCells
    35. When Cancer Cells Become the Enablers of an Antitumor Immune Response. Cancer Discov. 2022 10 05; 12(10):2244-2248. Ribas A, Haining WN, Schumacher TNM. PMID: 36196573.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    36. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197. Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. PMID: 36166727; PMCID: PMC9839305.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    37. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2023 01 20; 41(3):528-540. Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. PMID: 35998300; PMCID: PMC9870217.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCellsCTClinical Trials
    38. Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity. J Clin Invest. 2022 08 15; 132(16). Abt ER, Rashid K, Le TM, Li S, Lee HR, Lok V, Li L, Creech AL, Labora AN, Mandl HK, Lam AK, Cho A, Rezek V, Wu N, Abril-Rodriguez G, Rosser EW, Mittelman SD, Hugo W, Mehrling T, Bantia S, Ribas A, Donahue TR, Crooks GM, Wu TT, Radu CG. PMID: 35653193; PMCID: PMC9374381.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    39. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. Front Immunol. 2022; 13:897991. Hong DS, Gopal AK, Shoushtari AN, Patel SP, He AR, Doi T, Ramalingam SS, Patnaik A, Sandhu S, Chen Y, Davis CB, Fisher TS, Huang B, Fly KD, Ribas A. PMID: 35983060; PMCID: PMC9379324.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    40. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. J Immunol. 2022 08 15; 209(4):696-709. Lechner MG, Cheng MI, Patel AY, Hoang AT, Yakobian N, Astourian M, Pioso MS, Rodriguez ED, McCarthy EC, Hugo W, Angell TE, Drakaki A, Ribas A, Su MA. PMID: 35817515; PMCID: PMC9378719.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    41. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell. 2022 07 07; 185(14):2591-2608.e30. Biermann J, Melms JC, Amin AD, Wang Y, Caprio LA, Karz A, Tagore S, Barrera I, Ibarra-Arellano MA, Andreatta M, Fullerton BT, Gretarsson KH, Sahu V, Mangipudy VS, Nguyen TTT, Nair A, Rogava M, Ho P, Koch PD, Banu M, Humala N, Mahajan A, Walsh ZH, Shah SB, Vaccaro DH, Caldwell B, Mu M, Wünnemann F, Chazotte M, Berhe S, Luoma AM, Driver J, Ingham M, Khan SA, Rapisuwon S, Slingluff CL, Eigentler T, Röcken M, Carvajal R, Atkins MB, Davies MA, Agustinus A, Bakhoum SF, Azizi E, Siegelin M, Lu C, Carmona SJ, Hibshoosh H, Ribas A, Canoll P, Bruce JN, Bi WL, Agrawal P, Schapiro D, Hernando E, Macosko EZ, Chen F, Schwartz GK, Izar B. PMID: 35803246; PMCID: PMC9677434.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    42. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature. 2022 07; 607(7918):360-365. Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, Song D, Rommel PC, Radaelli E, Young RM, Leonard WJ, Ribas A, June CH, Garcia KC. PMID: 35676488; PMCID: PMC9283313.
      View in: PubMed   Mentions: 29     Fields:    Translation:AnimalsCells
    43. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). J Immunother Cancer. 2022 06; 10(6). Tawbi HA, Robert C, Brase JC, Gusenleitner D, Gasal E, Garrett J, Savchenko A, Görgün G, Flaherty KT, Ribas A, Dummer R, Schadendorf D, Long GV, Nathan PD, Ascierto PA. PMID: 35728875; PMCID: PMC9214378.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    44. Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. Clin Cancer Res. 2022 04 14; 28(8):1680-1689. Cristescu R, Nebozhyn M, Zhang C, Albright A, Kobie J, Huang L, Zhao Q, Wang A, Ma H, Alexander Cao Z, Morrissey M, Ribas A, Grivas P, Cescon DW, McClanahan TK, Snyder A, Ayers M, Lunceford J, Loboda A. PMID: 34965943.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    45. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. Future Oncol. 2022 Jun; 18(17):2041-2051. Schadendorf D, Dummer R, Robert C, Ribas A, Sullivan RJ, Panella T, McKean M, Santos ES, Brill K, Polli A, Pietro AD, Ascierto PA. PMID: 35272485.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    46. Spatial profiling reveals association between WNT pathway activation and T-cell exclusion in acquired resistance of synovial sarcoma to NY-ESO-1 transgenic T-cell therapy. J Immunother Cancer. 2022 03; 10(3). Campbell KM, Thaker M, Medina E, Kalbasi A, Singh A, Ribas A, Nowicki TS. PMID: 35264439; PMCID: PMC8915285.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    47. Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022 03 01; 12(3):644-653. Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A. PMID: 34764195; PMCID: PMC8904282.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    48. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022 03 03; 185(5):881-895.e20. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J, Kornilov SA, Scherler K, Pavlovitch-Bedzyk AJ, Dong S, Lausted C, Lee I, Fallen S, Dai CL, Baloni P, Smith B, Duvvuri VR, Anderson KG, Li J, Yang F, Duncombe CJ, McCulloch DJ, Rostomily C, Troisch P, Zhou J, Mackay S, DeGottardi Q, May DH, Taniguchi R, Gittelman RM, Klinger M, Snyder TM, Roper R, Wojciechowska G, Murray K, Edmark R, Evans S, Jones L, Zhou Y, Rowen L, Liu R, Chour W, Algren HA, Berrington WR, Wallick JA, Cochran RA, Micikas ME, ISB-Swedish COVID-19 Biobanking Unit, Wrin T, Petropoulos CJ, Cole HR, Fischer TD, Wei W, Hoon DSB, Price ND, Subramanian N, Hill JA, Hadlock J, Magis AT, Ribas A, Lanier LL, Boyd SD, Bluestone JA, Chu H, Hood L, Gottardo R, Greenberg PD, Davis MM, Goldman JD, Heath JR. PMID: 35216672; PMCID: PMC8786632.
      View in: PubMed   Mentions: 364     Fields:    Translation:HumansCells
    49. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. J Clin Oncol. 2022 05 01; 40(13):1428-1438. Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandalà M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. PMID: 35030011; PMCID: PMC9061149.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    50. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer. 2022 01; 10(1). Friedman CF, Spencer C, Cabanski CR, Panageas KS, Wells DK, Ribas A, Tawbi H, Tsai K, Postow M, Shoushtari A, Chapman P, Karakunnel J, Bucktrout S, Gherardini P, Hollmann TJ, Chen RO, Callahan M, LaVallee T, Ibrahim R, Wolchok J. PMID: 35074903; PMCID: PMC8788323.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    51. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007. Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM. PMID: 34326162; PMCID: PMC8799774.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCellsCTClinical Trials
    52. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. Eur J Cancer. 2022 01; 160:1-11. Maio M, Carlino MS, Joshua AM, McWhirter E, Ribas A, Ascierto PA, Miller WH, Butler MO, Ferrucci PF, Zielinski RR, Del Vecchio M, Gasal E, Ghori R, Diede SJ, Croydon E, Hamid O. PMID: 34801354.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    53. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021 11 16; 2(11):100449. Li YR, Zhou Y, Kim YJ, Zhu Y, Ma F, Yu J, Wang YC, Chen X, Li Z, Zeng S, Wang X, Lee D, Ku J, Tsao T, Hardoy C, Huang J, Cheng D, Montel-Hagen A, Seet CS, Crooks GM, Larson SM, Sasine JP, Wang X, Pellegrini M, Ribas A, Kohn DB, Witte O, Wang P, Yang L. PMID: 34841295; PMCID: PMC8607011.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    54. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proc Natl Acad Sci U S A. 2021 10 26; 118(43). Gangaev A, Rozeman EA, Rohaan MW, Isaeva OI, Philips D, Patiwael S, van den Berg JH, Ribas A, Schadendorf D, Schilling B, Schumacher TN, Blank CU, Haanen JBAG, Kvistborg P. PMID: 34670835; PMCID: PMC8639378.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    55. Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis. Cell Rep Med. 2021 10 19; 2(10):100419. Ferrian S, Liu CC, McCaffrey EF, Kumar R, Nowicki TS, Dawson DW, Baranski A, Glaspy JA, Ribas A, Bendall SC, Angelo M. PMID: 34755133; PMCID: PMC8561237.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    56. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res. 2021 10 01; 27(19):5225-5235. Ascierto PA, Dréno B, Larkin J, Ribas A, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Atkinson V, Dutriaux C, Garbe C, Hsu J, Jones S, Li H, McKenna E, Voulgari A, McArthur GA. PMID: 34158360.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    57. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. Eur J Cancer. 2021 11; 157:391-402. Hamid O, Robert C, Daud A, Carlino MS, Mitchell TC, Hersey P, Schachter J, Long GV, Hodi FS, Wolchok JD, Arance A, Grob JJ, Joshua AM, Weber JS, Mortier L, Jensen E, Diede SJ, Moreno BH, Ribas A. PMID: 34571336; PMCID: PMC9350885.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    58. How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. Blood Cancer Discov. 2021 11; 2(6):562-567. Ribas A, Dhodapkar MV, Campbell KM, Davies FE, Gore SD, Levy R, Greenberger LM. PMID: 34778796; PMCID: PMC8580613.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    59. Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni Ribas. J Nucl Med. 2021 Sep 01; 62(9):1178-1180. Czernin J, Radu C, Ribas A. PMID: 34475241.
      View in: PubMed   Mentions:    Fields:    
    60. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021 10 11; 39(10):1375-1387.e6. Wang Y, Liu S, Yang Z, Algazi AP, Lomeli SH, Wang Y, Othus M, Hong A, Wang X, Randolph CE, Jones AM, Bosenberg MW, Byrum SD, Tackett AJ, Lopez H, Yates C, Solit DB, Ribas A, Piva M, Moriceau G, Lo RS. PMID: 34416167; PMCID: PMC9126729.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimals
    61. Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun. 2021 Aug 12; 12(1):5022. Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, Hernandez-Aya L, Lawrence D, Lutzky J, Miller WH, Campbell KM, Delafont B, Marshall S, Mueller N, Robert C. PMID: 34385448; PMCID: PMC8360951.
      View in: PubMed   Mentions:    Fields:    
    62. Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. Cancer Discov. 2021 08; 11(8):1881-1885. Flaherty KT, Doroshow JH, Galbraith S, Ribas A, Kluetz PG, Pazdur R, Theoret MR. PMID: 34290074; PMCID: PMC8340848.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    63. Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects. PLoS One. 2021; 16(6):e0252597. Escuin-Ordinas H, Liu Y, Sun L, Hugo W, Dimatteo R, Huang RR, Krystofinski P, Azhdam A, Lee J, Comin-Anduix B, Cochran AJ, Lo RS, Segura T, Scumpia PO, Ribas A. PMID: 34161353; PMCID: PMC8221471.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    64. Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapy. J Clin Invest. 2021 06 15; 131(12). Kim YJ, Sheu KM, Tsoi J, Abril-Rodriguez G, Medina E, Grasso CS, Torrejon DY, Champhekar AS, Litchfield K, Swanton C, Speiser DE, Scumpia PO, Hoffmann A, Graeber TG, Puig-Saus C, Ribas A. PMID: 33914706; PMCID: PMC8203459.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    65. Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. Clin Cancer Res. 2021 08 15; 27(16):4500-4510. Brase JC, Walter RFH, Savchenko A, Gusenleitner D, Garrett J, Schimming T, Varaljai R, Castelletti D, Kim J, Dakappagari N, Schultz K, Robert C, Long GV, Nathan PD, Ribas A, Flaherty KT, Karaszewska B, Schachter J, Sucker A, Schmid KW, Zimmer L, Livingstone E, Gasal E, Schadendorf D, Roesch A. PMID: 34108180; PMCID: PMC9401540.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    66. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy. J Immunother Cancer. 2021 05; 9(5). Kohli K, Yao L, Nowicki TS, Zhang S, Black RG, Schroeder BA, Farrar EA, Cao J, Sloan H, Stief D, Cranmer LD, Wagner MJ, Hawkins DS, Pillarisetty VG, Ribas A, Campbell J, Pierce RH, Kim EY, Jones RL, Riddell SR, Yee C, Pollack SM. PMID: 33963013; PMCID: PMC8108691.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    67. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. Cancer Discov. 2021 09; 11(9):2158-2167. Lacouture ME, Wainberg ZA, Patel AB, Anadkat MJ, Stemmer SM, Shacham-Shmueli E, Medina E, Zelinger G, Shelach N, Ribas A. PMID: 33910927; PMCID: PMC8418997.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    68. Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. Cancer Discov. 2021 06; 11(6):1336-1344. Aldea M, Michot JM, Danlos FX, Ribas A, Soria JC. PMID: 33846172.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    69. IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. Cancer Discov. 2021 09; 11(9):2248-2265. Alizadeh D, Wong RA, Gholamin S, Maker M, Aftabizadeh M, Yang X, Pecoraro JR, Jeppson JD, Wang D, Aguilar B, Starr R, Larmonier CB, Larmonier N, Chen MH, Wu X, Ribas A, Badie B, Forman SJ, Brown CE. PMID: 33837065; PMCID: PMC8561746.
      View in: PubMed   Mentions: 55     Fields:    Translation:AnimalsCells
    70. RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets. Trends Pharmacol Sci. 2021 04; 42(4):268-282. Pan Y, Kadash-Edmondson KE, Wang R, Phillips J, Liu S, Ribas A, Aplenc R, Witte ON, Xing Y. PMID: 33711255; PMCID: PMC8761020.
      View in: PubMed   Mentions: 23     Fields:    
    71. T Cells as the Future of Cancer Therapy. Cancer Discov. 2021 04; 11(4):798-800. Ribas A. PMID: 33811114; PMCID: PMC8082738.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    72. Cardiotoxicities of novel cancer immunotherapies. Heart. 2021 11; 107(21):1694-1703. Stein-Merlob AF, Rothberg MV, Ribas A, Yang EH. PMID: 33722826.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    73. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 2021 03; 22(3):370-380. Syeda MM, Wiggins JM, Corless BC, Long GV, Flaherty KT, Schadendorf D, Nathan PD, Robert C, Ribas A, Davies MA, Grob JJ, Gasal E, Squires M, Marker M, Garrett J, Brase JC, Polsky D. PMID: 33587894; PMCID: PMC8034833.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    74. How Did We Get a COVID-19 Vaccine in Less Than 1 Year? Clin Cancer Res. 2021 04 15; 27(8):2136-2138. Wherry EJ, Jaffee EM, Warren N, D'Souza G, Ribas A, AACR COVID-19 and Cancer Task Force. PMID: 33542081; PMCID: PMC8052930.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsPHPublic Health
    75. At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer. Cancer Immunol Res. 2021 03; 9(3):261-264. Garassino MC, Ribas A. PMID: 33452008; PMCID: PMC8052929.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsPHPublic Health
    76. Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report. Immunotherapy. 2021 03; 13(4):283-288. Mulroy M, Ghafouri S, Sisk A, Ribas A, Goshtaseb R, Cherry G, Shen J. PMID: 33397120.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    77. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021 02; 144:182-191. Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, Hodi FS, Wolchok JD, Mitchell TC, Hersey P, Dronca R, Joseph RW, Boutros C, Min L, Long GV, Schachter J, Puzanov I, Dummer R, Lin J, Ibrahim N, Diede SJ, Carlino MS, Joshua AM. PMID: 33360855; PMCID: PMC8388128.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    78. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discov. 2021 02; 11(2):233-236. Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, Jaffee EM, Wherry EJ, Soria JC, D'Souza G, AACR COVID-19 and Cancer Task Force. PMID: 33355178; PMCID: PMC8053003.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansPHPublic Health
    79. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. Cancer Discov. 2021 03; 11(3):714-735. Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS. PMID: 33318037; PMCID: PMC7933113.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    80. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2021 Jan 11; 39(1):122. Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. PMID: 33306984; PMCID: PMC7885306.
      View in: PubMed   Mentions: 14     Fields:    
    81. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun. 2020 12 07; 11(1):6262. Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, Hernandez-Aya L, Lawrence D, Lutzky J, Miller WH, Campbell KM, Delafont B, Marshall S, Mueller N, Robert C. PMID: 33288749; PMCID: PMC7721806.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    82. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020 12; 8(2). Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM, Lotem M, Abu-Amna M, Gasal E, Ghori R, Diede SJ, Croydon ES, Ribas A, Ascierto PA, KEYNOTE-022 international team. PMID: 33361337; PMCID: PMC7768966.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    83. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science. 2020 11 27; 370(6520):1099-1104. Williams JZ, Allen GM, Shah D, Sterin IS, Kim KH, Garcia VP, Shavey GE, Yu W, Puig-Saus C, Tsoi J, Ribas A, Roybal KT, Lim WA. PMID: 33243890; PMCID: PMC8054651.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    84. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Rep Med. 2020 11 17; 1(8):100139. Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, Stein J, Tsai HL, Wang H, Belcaid Z, Murray J, Balan A, Ferreira L, Ross-Macdonald P, Wind-Rotolo M, Baras AS, Taube J, Karchin R, Scharpf RB, Grasso C, Ribas A, Pardoll DM, Topalian SL, Velculescu VE. PMID: 33294860; PMCID: PMC7691441.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCellsCTClinical Trials
    85. Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. Nat Cancer. 2020 12; 1(12):1167-1175. Cummings AL, Gukasyan J, Lu HY, Grogan T, Sunga G, Fares CM, Hornstein N, Zaretsky J, Carroll J, Bachrach B, Akingbemi WO, Li D, Noor Z, Lisberg A, Goldman JW, Elashoff D, Bui AAT, Ribas A, Dubinett SM, Rossetti M, Garon EB. PMID: 35121931.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    86. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Sci Transl Med. 2020 10 14; 12(565). Kalbasi A, Tariveranmoshabad M, Hakimi K, Kremer S, Campbell KM, Funes JM, Vega-Crespo A, Parisi G, Champekar A, Nguyen C, Torrejon D, Shin D, Zaretsky JM, Damoiseaux RD, Speiser DE, Lopez-Casas PP, Quintero M, Ribas A. PMID: 33055240; PMCID: PMC8053376.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    87. Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell. 2020 10 29; 183(3):818-834.e13. Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng AHC, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC, Tumor Neoantigen Selection Alliance, Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA. PMID: 33038342; PMCID: PMC7652061.
      View in: PubMed   Mentions: 157     Fields:    Translation:Humans
    88. Impact of COVID-19 Pandemic on Cancer Research. Cancer Cell. 2020 11 09; 38(5):591-593. Zon L, Gomes AP, Cance WG, Ribas A, Tuveson D, Postel-Vinay S, Massard C, Barlési F. PMID: 33086030; PMCID: PMC7543995.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    89. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568. Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. PMID: 33020646; PMCID: PMC8063889.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    90. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020 10; 26(10):1557-1563. Dummer R, Lebbé C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GV. PMID: 33020648.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    91. Raman-guided subcellular pharmaco-metabolomics for metastatic melanoma cells. Nat Commun. 2020 09 24; 11(1):4830. Du J, Su Y, Qian C, Yuan D, Miao K, Lee D, Ng AHC, Wijker RS, Ribas A, Levine RD, Heath JR, Wei L. PMID: 32973134; PMCID: PMC7518429.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    92. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941; PMCID: PMC7710628.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    93. Disparities in Cancer Prevention in the COVID-19 Era. Cancer Prev Res (Phila). 2020 11; 13(11):893-896. Carethers JM, Sengupta R, Blakey R, Ribas A, D'Souza G. PMID: 32943438; PMCID: PMC8212395.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsPHPublic Health
    94. IL-32γ potentiates tumor immunity in melanoma. JCI Insight. 2020 09 17; 5(18). Gruber T, Kremenovic M, Sadozai H, Rombini N, Baeriswyl L, Maibach F, Modlin RL, Gilliet M, von Werdt D, Hunger RE, Seyed Jafari SM, Parisi G, Abril-Rodriguez G, Ribas A, Schenk M. PMID: 32841222; PMCID: PMC7526542.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    95. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020 10 12; 38(4):500-515.e3. Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. PMID: 32916126; PMCID: PMC7872287.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansCells
    96. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials. J Transl Med. 2020 08 03; 18(1):294. Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dréno B. PMID: 32746839; PMCID: PMC7397682.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    97. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. JAMA Oncol. 2020 08 01; 6(8):1256-1264. Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O. PMID: 32672795; PMCID: PMC7366279.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    98. Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy. Cancer Discov. 2020 11; 10(11):1645-1653. Nowicki TS, Farrell C, Morselli M, Rubbi L, Campbell KM, Macabali MH, Berent-Maoz B, Comin-Anduix B, Pellegrini M, Ribas A. PMID: 32699033; PMCID: PMC7641915.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    99. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 10 01; 26(19):5086-5091. Carlino MS, Menzies AM, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Guminski AD, Kefford R, Wu H, Ibrahim N, Homet Moreno B, Long GV. PMID: 32605909.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    100. Prioritization of SARS-CoV-2 epitopes using a pan-HLA and global population inference approach. bioRxiv. 2020 Jun 29. Campbell KM, Steiner G, Wells DK, Ribas A, Kalbasi A. PMID: 32511325; PMCID: PMC7239055.
      View in: PubMed   Mentions: 3  
    101. Triple therapy for BRAFV600-mutated melanoma. Lancet. 2020 06 13; 395(10240):1814-1815. Ribas A. PMID: 32534635; PMCID: PMC8063890.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    102. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discov. 2020 08; 10(8):1140-1157. Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A. PMID: 32467343; PMCID: PMC7416458.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    103. Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. Nat Commun. 2020 05 11; 11(1):2345. Su Y, Ko ME, Cheng H, Zhu R, Xue M, Wang J, Lee JW, Frankiw L, Xu A, Wong S, Robert L, Takata K, Yuan D, Lu Y, Huang S, Ribas A, Levine R, Nolan GP, Wei W, Plevritis SK, Li G, Baltimore D, Heath JR. PMID: 32393797; PMCID: PMC7214418.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    104. Trying for a BRAF Slam Dunk. Cancer Discov. 2020 05; 10(5):640-642. Ribas A, Lo RS. PMID: 32357967; PMCID: PMC7363198.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    105. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. Eur J Cancer. 2020 05; 130:126-138. Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, Schadendorf D, Garbe C. PMID: 32179447.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    106. Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer. 2020 02; 1(2):264. Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. PMID: 35122015.
      View in: PubMed   Mentions:    Fields:    
    107. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat Commun. 2020 01 31; 11(1):660. Parisi G, Saco JD, Salazar FB, Tsoi J, Krystofinski P, Puig-Saus C, Zhang R, Zhou J, Cheung-Lau GC, Garcia AJ, Grasso CS, Tavaré R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu AM, Comin-Anduix B, Charych D, Ribas A. PMID: 32005809; PMCID: PMC6994533.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    108. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. Eur J Cancer. 2020 01; 125:114-120. Hauschild A, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, Blank CU, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A, Gasal E, Mookerjee B, Chapman PB. PMID: 31864178; PMCID: PMC8073226.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    109. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2019 Dec 10; 29(11):3766. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A. PMID: 31825850.
      View in: PubMed   Mentions: 52     Fields:    
    110. PAK4 inhibition improves PD-1 blockade immunotherapy. Nat Cancer. 2020; 1(1):46-58. Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. PMID: 34368780; PMCID: PMC8340852.
      View in: PubMed   Mentions: 46     Fields:    Translation:AnimalsCells
    111. Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis. Cell Discov. 2019; 5:62. Palaskas NJ, Garcia JD, Shirazi R, Shin DS, Puig-Saus C, Braas D, Ribas A, Graeber TG. PMID: 31798961; PMCID: PMC6877514.
      View in: PubMed   Mentions: 12  
    112. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53. Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. PMID: 31732523; PMCID: PMC6942621.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    113. Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. Cell Rep. 2019 10 15; 29(3):573-588.e7. Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, Gagnon A, Judson RL, Ballotti R, Ribas A, Herlyn M, Rocchi S, Brown KM, Hayward NK, Yeh I, Bastian BC. PMID: 31618628; PMCID: PMC6939448.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    114. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020 01; 20(1):25-39. Kalbasi A, Ribas A. PMID: 31570880; PMCID: PMC8499690.
      View in: PubMed   Mentions: 489     Fields:    Translation:HumansAnimalsCells
    115. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell. 2019 10 03; 25(4):542-557.e9. Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L. PMID: 31495780; PMCID: PMC7018522.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    116. Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood. Cell Rep. 2019 09 03; 28(10):2728-2738.e7. Peng S, Zaretsky JM, Ng AHC, Chour W, Bethune MT, Choi J, Hsu A, Holman E, Ding X, Guo K, Kim J, Xu AM, Heath JE, Noh WJ, Zhou J, Su Y, Lu Y, McLaughlin J, Cheng D, Witte ON, Baltimore D, Ribas A, Heath JR. PMID: 31484081; PMCID: PMC6774618.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    117. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Br J Cancer. 2019 10; 121(7):522-528. Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, Dréno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A. PMID: 31417188; PMCID: PMC6889491.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    118. Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019 Aug; 25(8):1319. Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O. PMID: 31267021.
      View in: PubMed   Mentions: 3     Fields:    
    119. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019 09; 20(9):1239-1251. Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV. PMID: 31345627.
      View in: PubMed   Mentions: 425     Fields:    Translation:HumansCTClinical Trials
    120. Gene editing: Towards the third generation of adoptive T-cell transfer therapies. Immunooncol Technol. 2019 Jul; 1:19-26. Puig-Saus C, Ribas A. PMID: 35755321; PMCID: PMC9216344.
      View in: PubMed   Mentions: 3  
    121. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019 06; 25(6):941-946. Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A. PMID: 31171878.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCTClinical Trials
    122. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019 06; 25(6):936-940. Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O. PMID: 31171879; PMCID: PMC8562134.
      View in: PubMed   Mentions: 154     Fields:    Translation:HumansCTClinical Trials
    123. Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance. PLoS Comput Biol. 2019 06; 15(6):e1007034. Su Y, Bintz M, Yang Y, Robert L, Ng AHC, Liu V, Ribas A, Heath JR, Wei W. PMID: 31166947; PMCID: PMC6576794.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    124. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. Eur J Cancer. 2019 07; 116:45-55. Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, McArthur GA, Dréno B, McKenna E, Zhu Q, Mun Y, Ascierto PA. PMID: 31173962.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    125. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019 08 15; 381(7):626-636. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. PMID: 31166680.
      View in: PubMed   Mentions: 451     Fields:    Translation:HumansCTClinical Trials
    126. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res. 2019 06 01; 25(11):3469-3470. Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. PMID: 31160495; PMCID: PMC6662573.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    127. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 08 15; 25(16):5061-5068. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. PMID: 31113840; PMCID: PMC6901027.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    128. Interleukin 32 expression in human melanoma. J Transl Med. 2019 04 05; 17(1):113. Paz H, Tsoi J, Kalbasi A, Grasso CS, McBride WH, Schaue D, Butterfield LH, Maurer DM, Ribas A, Graeber TG, Economou JS. PMID: 30953519; PMCID: PMC6449995.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    129. Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. Eur J Cancer. 2019 05; 112:29-31. Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A. PMID: 30903870.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    130. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunol Immunother. 2019 Jun; 68(6):897-905. Chat V, Ferguson R, Simpson D, Kazlow E, Lax R, Moran U, Pavlick A, Frederick D, Boland G, Sullivan R, Ribas A, Flaherty K, Osman I, Weber J, Kirchhoff T. PMID: 30863922; PMCID: PMC6531317.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    131. Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAFV600-mutated Metastatic Melanoma. Clin Cancer Res. 2019 06 01; 25(11):3239-3246. Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A. PMID: 30824584; PMCID: PMC8083896.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    132. T cell antigen discovery via trogocytosis. Nat Methods. 2019 02; 16(2):183-190. Li G, Bethune MT, Wong S, Joglekar AV, Leonard MT, Wang JK, Kim JT, Cheng D, Peng S, Zaretsky JM, Su Y, Luo Y, Heath JR, Ribas A, Witte ON, Baltimore D. PMID: 30700903; PMCID: PMC6719556.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansAnimalsCells
    133. T cell antigen discovery via signaling and antigen-presenting bifunctional receptors. Nat Methods. 2019 02; 16(2):191-198. Joglekar AV, Leonard MT, Jeppson JD, Swift M, Li G, Wong S, Peng S, Zaretsky JM, Heath JR, Ribas A, Bethune MT, Baltimore D. PMID: 30700902; PMCID: PMC6755906.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    134. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. Clin Cancer Res. 2019 04 01; 25(7):2096-2108. Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A. PMID: 30573690; PMCID: PMC6445780.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    135. Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 Dec 01; 24(23):6098. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. PMID: 30510087.
      View in: PubMed   Mentions: 10     Fields:    
    136. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. Clin Cancer Res. 2019 02 01; 25(3):1000-1011. Puig-Saus C, Parisi G, Garcia-Diaz A, Krystofinski PE, Sandoval S, Zhang R, Champhekar AS, McCabe J, Cheung-Lau GC, Truong NA, Vega-Crespo A, Komenan MDS, Pang J, Macabali MH, Saco JD, Goodwin JL, Bolon B, Seet CS, Montel-Hagen A, Crooks GM, Hollis RP, Campo-Fernandez B, Bischof D, Cornetta K, Gschweng EH, Adelson C, Nguyen A, Yang L, Witte ON, Baltimore D, Comin-Anduix B, Kohn DB, Wang X, Cabrera P, Kaplan-Lefko PJ, Berent-Maoz B, Ribas A. PMID: 30409823; PMCID: PMC6359988.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    137. Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. JCO Precis Oncol. 2018 Nov; 2:1-17. Lu W, Burton L, Larkin J, Chapman PB, Ascierto PA, Ribas A, Robert C, Sosman JA, McArthur GA, Chang I, Caro I, Penuel E, Yan Y, Wongchenko MJ. PMID: 35135117.
      View in: PubMed   Mentions: 1     Fields:    
    138. Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. JCO Precis Oncol. 2018 Nov; 2:1-18. Wongchenko MJ, Ribas A, Ascierto PA, Dréno B, Maria di Giacomo A, Garbe C, Chang I, Hsu J, Rooney I, Lu W, Koeppen H, Larkin J, Yan Y, McArthur GA. PMID: 35135126.
      View in: PubMed   Mentions: 1     Fields:    
    139. Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proc Natl Acad Sci U S A. 2018 11 06; 115(45):E10702-E10711. Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D. PMID: 30348802; PMCID: PMC6233129.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimals
    140. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018 10 12; 362(6411). Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. PMID: 30309915; PMCID: PMC6718162.
      View in: PubMed   Mentions: 972     Fields:    Translation:HumansCells
    141. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. JAMA Oncol. 2018 10 01; 4(10):1382-1388. Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA. PMID: 30073321; PMCID: PMC6233771.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    142. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018 09; 119(6):670-674. Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M. PMID: 30202085; PMCID: PMC6173747.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    143. The new era of adjuvant therapies for melanoma. Nat Rev Clin Oncol. 2018 09; 15(9):535-536. Eggermont AMM, Robert C, Ribas A. PMID: 29849093.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    144. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov. 2018 10; 8(10):1250-1257. Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. PMID: 30154193; PMCID: PMC6719557.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCTClinical Trials
    145. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2018 08 09; 174(4):1031-1032. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. PMID: 30096300.
      View in: PubMed   Mentions: 76     Fields:    
    146. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018 09; 101:236-243. Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A. PMID: 30096704.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    147. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019 02 15; 25(4):1233-1238. Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. PMID: 30054281; PMCID: PMC6348141.
      View in: PubMed   Mentions: 168     Fields:    Translation:HumansCells
    148. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018 07; 559(7714):405-409. Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A. PMID: 29995861; PMCID: PMC6239417.
      View in: PubMed   Mentions: 351     Fields:    Translation:HumansAnimalsCells
    149. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res. 2018 11 01; 24(21):5347-5356. Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT. PMID: 29898988; PMCID: PMC6324578.
      View in: PubMed   Mentions: 154     Fields:    Translation:HumansAnimalsCells
    150. Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. Cancer Discov. 2018 08; 8(8):935-943. Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, Cochran AJ, Economou JS, Tumeh PC, Puig-Saus C, Ribas A. PMID: 29899062; PMCID: PMC6076867.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCells
    151. Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. J Immunother. 2018 Jun; 41(5):248-259. Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix B. PMID: 29470191; PMCID: PMC5959255.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    152. Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs. J Control Release. 2018 07 28; 282:156-165. Zhu S, Li S, Escuin-Ordinas H, Dimatteo R, Xi W, Ribas A, Segura T. PMID: 29751029; PMCID: PMC6082662.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    153. Anti-PD-1 antibody treatment for melanoma. Lancet Oncol. 2018 05; 19(5):e219. Ribas A, Kirkwood JM, Flaherty KT. PMID: 29726378.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    154. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 10 15; 24(20):4960-4967. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. PMID: 29685882; PMCID: PMC6916264.
      View in: PubMed   Mentions: 126     Fields:    
    155. Antigen Presentation Keeps Trending in Immunotherapy Resistance. Clin Cancer Res. 2018 07 15; 24(14):3239-3241. Kalbasi A, Ribas A. PMID: 29674509; PMCID: PMC6050090.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    156. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018 05 14; 33(5):890-904.e5. Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, Braas D, Grasso CS, Palaskas N, Ribas A, Graeber TG. PMID: 29657129; PMCID: PMC5953834.
      View in: PubMed   Mentions: 335     Fields:    Translation:HumansCells
    157. Cancer immunotherapy using checkpoint blockade. Science. 2018 03 23; 359(6382):1350-1355. Ribas A, Wolchok JD. PMID: 29567705; PMCID: PMC7391259.
      View in: PubMed   Mentions: 2365     Fields:    Translation:Humans
    158. Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov. 2018 06; 8(6):730-749. Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski P, Leiserson MDM, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U. PMID: 29510987; PMCID: PMC5984687.
      View in: PubMed   Mentions: 242     Fields:    Translation:HumansCells
    159. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018 03 02; 359(6379):1037-1042. Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC. PMID: 29496879; PMCID: PMC5947856.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansAnimalsCells
    160. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 02 22; 3(4). Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT. PMID: 29467321; PMCID: PMC5916243.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    161. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma. Br J Cancer. 2018 03 20; 118(6):777-784. Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A. PMID: 29438370; PMCID: PMC5877437.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    162. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. PMID: 29449192; PMCID: PMC5840029.
      View in: PubMed   Mentions: 281     Fields:    Translation:Humans
    163. A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication. PLoS One. 2018; 13(1):e0191634. Zhou J, Bethune MT, Malkova N, Sutherland AM, Comin-Anduix B, Su Y, Baltimore D, Ribas A, Heath JR. PMID: 29360859; PMCID: PMC5779691.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    164. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815. Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A. PMID: 29358500.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    165. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 02 08; 172(4):825-840.e18. Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, Takeda S, Tafreshian KN, Rowinsky E, Szarek M, Waltzman RJ, Mcmillan EA, Zhao C, Mita M, Mita A, Chmielowski B, Postow MA, Ribas A, Mucida D, Tavazoie SF. PMID: 29336888; PMCID: PMC5846344.
      View in: PubMed   Mentions: 202     Fields:    Translation:AnimalsCells
    166. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 01 18; 553(7688):347-350. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A. PMID: 29320474; PMCID: PMC5773412.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansCells
    167. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018 Jan/Feb; 24(1):47-53. Nowicki TS, Hu-Lieskovan S, Ribas A. PMID: 29360728; PMCID: PMC5785093.
      View in: PubMed   Mentions: 172     Fields:    Translation:HumansAnimals
    168. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018 06 10; 36(17):1668-1674. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS. PMID: 29283791.
      View in: PubMed   Mentions: 177     Fields:    Translation:HumansCTClinical Trials
    169. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018 02; 8(2):184-195. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. PMID: 29247021.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCTClinical Trials
    170. Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A. 2017 12 26; 114(52):13679-13684. Su Y, Wei W, Robert L, Xue M, Tsoi J, Garcia-Diaz A, Homet Moreno B, Kim J, Ng RH, Lee JW, Koya RC, Comin-Anduix B, Graeber TG, Ribas A, Heath JR. PMID: 29229836; PMCID: PMC5748184.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCells
    171. Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell Melanoma Res. 2018 07; 31(4):516-522. Wongchenko MJ, Ribas A, Dréno B, Ascierto PA, McArthur GA, Gallo JD, Rooney IA, Hsu J, Koeppen H, Yan Y, Larkin J. PMID: 29156488.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    172. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res. 2017 12; 27(6):585-590. Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O. PMID: 29076950.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    173. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45. Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A. PMID: 28961465.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    174. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. 2018 08; 59(8):1785-1796. Roberts ZJ, Better M, Bot A, Roberts MR, Ribas A. PMID: 29058502.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    175. High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585. Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE. PMID: 28994212; PMCID: PMC5673911.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    176. Endocrinopathies with use of cancer immunotherapies. Clin Endocrinol (Oxf). 2018 02; 88(2):327-332. Villa NM, Farahmand A, Du L, Yeh MW, Smooke-Praw S, Ribas A, Chmielowski B, Cherry G, Leung AM. PMID: 28941311; PMCID: PMC5771947.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    177. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. PMID: 28886381; PMCID: PMC8034392.
      View in: PubMed   Mentions: 664     Fields:    Translation:HumansCellsCTClinical Trials
    178. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov. 2017 11; 7(11):1248-1265. Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. PMID: 28864476; PMCID: PMC6668729.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimalsCells
    179. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017 09; 83:247-257. Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. PMID: 28756137.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    180. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Oct 21; 390(10105):1853-1862. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. PMID: 28822576.
      View in: PubMed   Mentions: 491     Fields:    Translation:HumansCTClinical Trials
    181. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nat Commun. 2017 08 14; 8(1):241. Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG. PMID: 28808226; PMCID: PMC5556071.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    182. Collaborative Care in Melanoma: The Essential Role of the Nurse
. Clin J Oncol Nurs. 2017 08 01; 21(4 Suppl):4-6. Kirkwood JM, Ribas A. PMID: 28738052.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    183. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017 09; 18(9):1202-1210. Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. PMID: 28729151.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCTClinical Trials
    184. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017 Aug 01; 127(8):2930-2940. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK. PMID: 28650338; PMCID: PMC5531419.
      View in: PubMed   Mentions: 1601     Fields:    Translation:HumansCellsCTClinical Trials
    185. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Res. 2017 09 01; 77(17):4697-4709. Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M. PMID: 28652246.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansAnimalsCells
    186. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J Transl Med. 2017 06 24; 15(1):146. de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B. PMID: 28646893; PMCID: PMC5483259.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    187. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017 09; 82:45-55. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C. PMID: 28648698.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCTClinical Trials
    188. SnapShot: Immune Checkpoint Inhibitors. Cancer Cell. 2017 06 12; 31(6):848-848.e1. Abril-Rodriguez G, Ribas A. PMID: 28609660.
      View in: PubMed   Mentions: 137     Fields:    Translation:Humans
    189. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res. 2017 Sep 01; 23(17):5238-5245. Wongchenko MJ, McArthur GA, Dréno B, Larkin J, Ascierto PA, Sosman J, Andries L, Kockx M, Hurst SD, Caro I, Rooney I, Hegde PS, Molinero L, Yue H, Chang I, Amler L, Yan Y, Ribas A. PMID: 28536307.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    190. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017 05 09; 19(6):1189-1201. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A. PMID: 28494868; PMCID: PMC6420824.
      View in: PubMed   Mentions: 807     Fields:    Translation:HumansCells
    191. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017 Aug; 14(8):463-482. Luke JJ, Flaherty KT, Ribas A, Long GV. PMID: 28374786.
      View in: PubMed   Mentions: 542     Fields:    Translation:Humans
    192. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget. 2017 Mar 14; 8(11):17795-17809. Caenepeel S, Cooke K, Wadsworth S, Huang G, Robert L, Moreno BH, Parisi G, Cajulis E, Kendall R, Beltran P, Ribas A, Coxon A, Hughes PE. PMID: 28147313; PMCID: PMC5392287.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    193. Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping. Biotechniques. 2017 03 01; 62(3):123-130. Bethune MT, Comin-Anduix B, Hwang Fu YH, Ribas A, Baltimore D. PMID: 28298179.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    194. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017 02 09; 168(4):707-723. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. PMID: 28187290; PMCID: PMC5391692.
      View in: PubMed   Mentions: 2040     Fields:    Translation:HumansAnimalsCells
    195. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2017 01 26; 168(3):542. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. PMID: 28129544.
      View in: PubMed   Mentions: 184     Fields:    
    196. New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. Cancer J. 2017 Jan/Feb; 23(1):10-22. Hu-Lieskovan S, Ribas A. PMID: 28114250; PMCID: PMC5844278.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    197. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. Cancer Immunol Res. 2017 02; 5(2):118-126. Nowicki TS, Akiyama R, Huang RR, Shintaku IP, Wang X, Tumeh PC, Singh A, Chmielowski B, Denny C, Federman N, Ribas A. PMID: 28039162; PMCID: PMC5290092.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    198. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 2017 02; 7(2):188-201. Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Rodriguez GA, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A. PMID: 27903500; PMCID: PMC5296316.
      View in: PubMed   Mentions: 606     Fields:    Translation:HumansCells
    199. What does PD-L1 positive or negative mean? J Exp Med. 2016 12 12; 213(13):2835-2840. Ribas A, Hu-Lieskovan S. PMID: 27903604; PMCID: PMC5154949.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansAnimalsCells
    200. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016 Dec; 17(12):1743-1754. Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. PMID: 27864013.
      View in: PubMed   Mentions: 128     Fields:    Translation:Humans
    201. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 12; 34(34):4102-4109. Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. PMID: 27863197; PMCID: PMC5562434.
      View in: PubMed   Mentions: 291     Fields:    Translation:HumansCTClinical Trials
    202. Cancer Research in the 21st Century. Ann Surg. 2016 10; 264(4):555-65. Economou JS, Slamon DJ, Ribas A, Phelps ME. PMID: 27537535.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    203. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 02; 35(1):47-58. Adjei AA, LoRusso P, Ribas A, Sosman JA, Pavlick A, Dy GK, Zhou X, Gangolli E, Kneissl M, Faucette S, Neuwirth R, Bózon V. PMID: 27650277; PMCID: PMC5306265.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    204. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov. 2016; 2:16028. Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, Lo RS, Graeber TG. PMID: 27648299; PMCID: PMC5012007.
      View in: PubMed   Mentions: 33  
    205. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016 11; 67:46-54. Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A. PMID: 27596353.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    206. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol Res. 2016 10; 4(10):845-857. Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A. PMID: 27589875; PMCID: PMC5050168.
      View in: PubMed   Mentions: 87     Fields:    Translation:AnimalsCells
    207. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Nov 15; 122(21):3354-3362. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. PMID: 27533633; PMCID: PMC5134420.
      View in: PubMed   Mentions: 112     Fields:    Translation:Humans
    208. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nat Commun. 2016 08 01; 7:12348. Escuin-Ordinas H, Li S, Xie MW, Sun L, Hugo W, Huang RR, Jiao J, de-Faria FM, Realegeno S, Krystofinski P, Azhdam A, Komenan SM, Atefi M, Comin-Anduix B, Pellegrini M, Cochran AJ, Modlin RL, Herschman HR, Lo RS, McBride WH, Segura T, Ribas A. PMID: 27476449; PMCID: PMC4974650.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    209. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 Sep; 17(9):1248-60. Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J. PMID: 27480103.
      View in: PubMed   Mentions: 354     Fields:    Translation:HumansCTClinical Trials
    210. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016 Sep 01; 375(9):819-29. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. PMID: 27433843; PMCID: PMC5007206.
      View in: PubMed   Mentions: 1420     Fields:    Translation:HumansCells
    211. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Sep 08; 537(7619):254. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. PMID: 27383789.
      View in: PubMed   Mentions: 5     Fields:    
    212. CRAF R391W is a melanoma driver oncogene. Sci Rep. 2016 06 08; 6:27454. Atefi M, Titz B, Tsoi J, Avramis E, Le A, Ng C, Lomova A, Lassen A, Friedman M, Chmielowski B, Ribas A, Graeber TG. PMID: 27273450; PMCID: PMC4897636.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    213. CANCER IMMUNOLOGY. The "cancer immunogram". Science. 2016 May 06; 352(6286):658-60. Blank CU, Haanen JB, Ribas A, Schumacher TN. PMID: 27151852.
      View in: PubMed   Mentions: 328     Fields:    Translation:HumansAnimalsCells
    214. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. PMID: 27092830.
      View in: PubMed   Mentions: 477     Fields:    Translation:HumansCTClinical Trials
    215. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. PMID: 27087480; PMCID: PMC5228487.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    216. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14; 532(7598):250-4. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. PMID: 27042933; PMCID: PMC4833579.
      View in: PubMed   Mentions: 187     Fields:    Translation:HumansAnimalsCells
    217. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016 Mar 24; 165(1):35-44. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. PMID: 26997480; PMCID: PMC4808437.
      View in: PubMed   Mentions: 1527     Fields:    Translation:HumansCells
    218. Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer. 2016; 4:15. Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA, Cancer Immunotherapy Trials Network (CITN). PMID: 26981245; PMCID: PMC4791805.
      View in: PubMed   Mentions: 30     Fields:    
    219. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016 05 01; 34(13):1510-7. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD. PMID: 26951310; PMCID: PMC5070547.
      View in: PubMed   Mentions: 313     Fields:    Translation:HumansCTClinical Trials
    220. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol. 2016 02; 28(1):73-80. Robert L, Ribas A, Hu-Lieskovan S. PMID: 26861544; PMCID: PMC4933650.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    221. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016 Mar; 4(3):194-203. Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B. PMID: 26787823; PMCID: PMC4775381.
      View in: PubMed   Mentions: 192     Fields:    Translation:HumansCellsCTClinical Trials
    222. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016 Jan; 8(1):48-56. Eroglu Z, Ribas A. PMID: 26753005; PMCID: PMC4699264.
      View in: PubMed   Mentions: 124  
    223. Targeted Therapy for Melanoma. Cancer Treat Res. 2016; 167:251-62. Wong DJ, Ribas A. PMID: 26601866.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    224. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer. 2016 Jan; 53:125-34. Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. PMID: 26707829.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    225. Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov. 2016 Mar; 15(3):204-16. Heath JR, Ribas A, Mischel PS. PMID: 26669673; PMCID: PMC4883669.
      View in: PubMed   Mentions: 182     Fields:    Translation:HumansAnimals
    226. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016 Mar; 13(3):143-58. Smyth MJ, Ngiow SF, Ribas A, Teng MW. PMID: 26598942.
      View in: PubMed   Mentions: 392     Fields:    Translation:HumansAnimalsCells
    227. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2016 Jan; 126(1):402-3. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ. PMID: 26595810; PMCID: PMC4701538.
      View in: PubMed   Mentions: 9     Fields:    
    228. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015 Dec; 51(18):2792-9. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. PMID: 26608120; PMCID: PMC4666799.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansCells
    229. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Res. 2016 Jan 01; 76(1):73-82. Tavaré R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, Witte ON, Ribas A, Wu AM. PMID: 26573799; PMCID: PMC4703530.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansAnimalsCells
    230. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015 Oct; 16(13):1389-98. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C. PMID: 26433819.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCTClinical Trials
    231. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget. 2015 Sep 22; 6(28):24823-41. Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C, Pisanu ME, Coluccia P, Camerlingo R, Roscilli G, Ribas A, Di Napoli A, Torrisi MR, Aurisicchio L, Ascierto PA, Mancini R, Ciliberto G. PMID: 26208478; PMCID: PMC4694796.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    232. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov; 51(17):2689-97. Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. PMID: 26364516; PMCID: PMC4821004.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    233. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 10; 162(6):1271-85. Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. PMID: 26359985; PMCID: PMC4821508.
      View in: PubMed   Mentions: 305     Fields:    Translation:HumansCells
    234. Releasing the Brakes on Cancer Immunotherapy. N Engl J Med. 2015 Oct 15; 373(16):1490-2. Ribas A. PMID: 26348216.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansAnimalsCells
    235. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology. 2016 Jul; 5(7):e1052212. Homet Moreno B, Mok S, Comin-Anduix B, Hu-Lieskovan S, Ribas A. PMID: 27622011; PMCID: PMC5006894.
      View in: PubMed   Mentions: 49     Fields:    
    236. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov. 2015 Sep; 5(9):915-9. Ribas A. PMID: 26272491; PMCID: PMC4560619.
      View in: PubMed   Mentions: 285     Fields:    Translation:HumansAnimalsCells
    237. Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2015 Jul 02; 14:128. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. PMID: 26134498; PMCID: PMC4488977.
      View in: PubMed   Mentions: 4     Fields:    
    238. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. PMID: 26115796; PMCID: PMC9004487.
      View in: PubMed   Mentions: 683     Fields:    Translation:HumansCTClinical Trials
    239. Excluding T Cells: Is β-Catenin the Full Story? Cancer Cell. 2015 Jun 08; 27(6):749-50. Hu-Lieskovan S, Homet Moreno B, Ribas A. PMID: 26058073.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    240. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015 Jun 01; 75(11):2139-45. Teng MW, Ngiow SF, Ribas A, Smyth MJ. PMID: 25977340; PMCID: PMC4452411.
      View in: PubMed   Mentions: 693     Fields:    Translation:HumansCells
    241. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015 Aug 01; 386(9992):444-51. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. PMID: 26037941.
      View in: PubMed   Mentions: 484     Fields:    Translation:HumansCTClinical Trials
    242. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015 Jul; 51(11):1435-43. Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB. PMID: 25980594; PMCID: PMC5087591.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    243. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer. 2015 May 05; 15:356. Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A. PMID: 25939769; PMCID: PMC4432503.
      View in: PubMed   Mentions: 33     Fields:    Translation:AnimalsCells
    244. Melanoma. Nat Rev Dis Primers. 2015 04 23; 1:15003. Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A. PMID: 27188223.
      View in: PubMed   Mentions: 227     Fields:    Translation:HumansCells
    245. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25; 372(26):2521-32. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 investigators. PMID: 25891173.
      View in: PubMed   Mentions: 2336     Fields:    Translation:HumansCTClinical Trials
    246. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18; 7(279):279ra41. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A. PMID: 25787767; PMCID: PMC4765379.
      View in: PubMed   Mentions: 283     Fields:    Translation:HumansAnimalsCells
    247. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015 May; 51(7):833-40. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV. PMID: 25794603.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    248. Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015 Mar; 25(3):399-400. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. PMID: 25732764; PMCID: PMC4349252.
      View in: PubMed   Mentions: 4     Fields:    
    249. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology. 2015 Apr; 4(4):e998538. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. PMID: 26137416; PMCID: PMC4485711.
      View in: PubMed   Mentions: 78     Fields:    
    250. Anti-PD-1 therapy in melanoma. Semin Oncol. 2015 Jun; 42(3):466-73. Homet Moreno B, Parisi G, Robert L, Ribas A. PMID: 25965365.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    251. Gauging the Long-Term Benefits of Ipilimumab in Melanoma. J Clin Oncol. 2015 Jun 10; 33(17):1865-6. Ribas A, Flaherty KT. PMID: 25667273.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    252. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer. 2015 Feb 03; 14:27. Atefi M, Titz B, Avramis E, Ng C, Wong DJ, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber TG, Ribas A. PMID: 25645078; PMCID: PMC4320814.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    253. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol. 2015 Apr; 33:23-35. Shin DS, Ribas A. PMID: 25621841.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansAnimalsCells
    254. MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells. Proc Natl Acad Sci U S A. 2015 Feb 03; 112(5):E420-9. Ploper D, Taelman VF, Robert L, Perez BS, Titz B, Chen HW, Graeber TG, von Euw E, Ribas A, De Robertis EM. PMID: 25605940; PMCID: PMC4321275.
      View in: PubMed   Mentions: 132     Fields:    Translation:HumansCells
    255. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. PMID: 25600339; PMCID: PMC4326539.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCells
    256. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015 Feb; 25(2):208-24. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. PMID: 25582080; PMCID: PMC4650573.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansAnimalsCells
    257. Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol. 2015 Jan; 16(1):15-7. Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. PMID: 25638540.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    258. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014 Dec 15; 5:5712. Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS. PMID: 25502142; PMCID: PMC4428333.
      View in: PubMed   Mentions: 315     Fields:    Translation:HumansAnimalsCells
    259. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27; 515(7528):568-71. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PMID: 25428505; PMCID: PMC4246418.
      View in: PubMed   Mentions: 3131     Fields:    Translation:HumansCellsCTClinical Trials
    260. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014 Dec 04; 371(23):2189-2199. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA. PMID: 25409260; PMCID: PMC4315319.
      View in: PubMed   Mentions: 2130     Fields:    Translation:Humans
    261. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 01; 372(1):30-9. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. PMID: 25399551.
      View in: PubMed   Mentions: 1013     Fields:    Translation:HumansCTClinical Trials
    262. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277. Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. PMID: 25348889; PMCID: PMC4232645.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    263. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014 Nov 20; 32(33):3771-8. Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK. PMID: 25332243; PMCID: PMC4226807.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    264. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014 Nov 13; 371(20):1867-76. Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. PMID: 25265494.
      View in: PubMed   Mentions: 797     Fields:    Translation:HumansCTClinical Trials
    265. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014 Nov 13; 371(20):1877-88. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K. PMID: 25265492.
      View in: PubMed   Mentions: 723     Fields:    Translation:HumansCTClinical Trials
    266. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb 01; 121(3):432-440. Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA. PMID: 25250858; PMCID: PMC4304973.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCellsCTClinical Trials
    267. T-cell immunotherapy: looking forward. Mol Ther. 2014 Sep; 22(9):1564-74. Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, Powell D, Ribas A, Rosenberg S, Sadelain M, Till B, Patterson AP, Jambou RC, Rosenthal E, Gargiulo L, Montgomery M, Kohn DB. PMID: 25186558; PMCID: PMC4435492.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    268. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014 Aug 20; 13:194. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. PMID: 25142146; PMCID: PMC4155088.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    269. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. 2014 Aug; 132(8):1005-9. McCannel TA, Chmielowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA, McCannel CA. PMID: 24852144.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    270. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci U S A. 2014 Aug 05; 111(31):11449-54. Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME, Yen Y. PMID: 25049380; PMCID: PMC4128111.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansAnimalsPHPublic HealthCTClinical Trials
    271. HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res. 2014 Sep 15; 74(18):5173-83. Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, Witte ON, Kohn DB. PMID: 25038231; PMCID: PMC4167467.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    272. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA. PMID: 25037139.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCTClinical Trials
    273. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. PMID: 25034862.
      View in: PubMed   Mentions: 778     Fields:    Translation:HumansCTClinical Trials
    274. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res. 2014 Oct; 2(10):981-7. Carson WE, Unger JM, Sosman JA, Flaherty LE, Tuthill RJ, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A, Sondak VK. PMID: 24994597; PMCID: PMC4185232.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    275. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res. 2014 Oct 01; 20(19):4982-4. Ribas A, Tumeh PC. PMID: 24970841; PMCID: PMC4184978.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    276. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology. 2014; 3:e29244. Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, Ribas A. PMID: 25083336; PMCID: PMC4108466.
      View in: PubMed   Mentions: 50     Fields:    
    277. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014 Jul 20; 32(21):2248-54. Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. PMID: 24958825; PMCID: PMC4164812.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    278. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014 May 28; 6(238):238ra70. Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, Fong L. PMID: 24871131; PMCID: PMC4558099.
      View in: PubMed   Mentions: 215     Fields:    Translation:Humans
    279. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014 Jul 01; 20(13):3446-57. Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. PMID: 24812408; PMCID: PMC4079734.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansCells
    280. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer. 2014 Apr 16; 13:83. Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, Ribas A. PMID: 24735930; PMCID: PMC4021505.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    281. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. PMID: 24634374; PMCID: PMC4070853.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    282. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 01; 20(9):2424-32. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, Koya RC, Graeber TG, Robins H, Ribas A. PMID: 24583799; PMCID: PMC4008652.
      View in: PubMed   Mentions: 200     Fields:    Translation:HumansCells
    283. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2014 Apr 15; 74(8):2340-50. Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB. PMID: 24576830; PMCID: PMC4005042.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCells
    284. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar; 15(3):323-32. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A. PMID: 24508103; PMCID: PMC4382632.
      View in: PubMed   Mentions: 384     Fields:    Translation:HumansCTClinical Trials
    285. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014 May; 2(5):459-68. Wong DJ, Rao A, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix B. PMID: 24795358; PMCID: PMC4010948.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    286. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014 Apr; 4(4):423-33. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA. PMID: 24469106; PMCID: PMC4110245.
      View in: PubMed   Mentions: 151     Fields:    Translation:HumansCells
    287. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014 Apr; 54(4):368-74. Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF. PMID: 24374975.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    288. Novel insights/translational implication from the emerging biology of melanoma. Methods Mol Biol. 2014; 1102:3-9. Ribas A. PMID: 24258970.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    289. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24. Flaherty L, Hamid O, Linette G, Schuchter L, Hallmeyer S, Gonzalez R, Cowey CL, Pavlick A, Kudrik F, Curti B, Lawson D, Chapman PB, Margolin K, Ribas A, McDermott D, Flaherty K, Cranmer L, Hodi FS, Day BM, Linke R, Hainsworth J. PMID: 24445759; PMCID: PMC4705837.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    290. New drug targets in metastatic melanoma. J Pathol. 2014 Jan; 232(2):134-41. Homet B, Ribas A. PMID: 24027077.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    291. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol Oncol. 2014 Mar; 8(2):250-60. Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A. PMID: 24345644; PMCID: PMC3943738.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    292. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79. Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS. PMID: 24265152; PMCID: PMC3893054.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansCells
    293. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. PMID: 24265155; PMCID: PMC3936420.
      View in: PubMed   Mentions: 493     Fields:    Translation:HumansCells
    294. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014 Jan 01; 74(1):153-161. Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, Graeber T, West BL, Bollag G, Ribas A. PMID: 24247719; PMCID: PMC3947337.
      View in: PubMed   Mentions: 171     Fields:    Translation:AnimalsCells
    295. Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829. Ibarrondo FJ, Yang OO, Chodon T, Avramis E, Lee Y, Sazegar H, Jalil J, Chmielowski B, Koya RC, Schmid I, Gomez-Navarro J, Jamieson BD, Ribas A, Comin-Anduix B. PMID: 24167550; PMCID: PMC3805549.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    296. PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. J Immunother Cancer. 2013; 1:14. Escuin-Ordinas H, Elliott MW, Atefi M, Lee M, Ng C, Wei L, Comin-Anduix B, Montecino-Rodriguez E, Avramis E, Radu C, Sharp LL, Ribas A. PMID: 24829750; PMCID: PMC4019904.
      View in: PubMed   Mentions: 9     Fields:    
    297. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013 Sep 10; 31(26):3205-11. Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin AM, Mazumdar J, Goodman VL, Trefzer U. PMID: 23918947.
      View in: PubMed   Mentions: 179     Fields:    Translation:HumansCTClinical Trials
    298. Reply to K.S. Wilson et al. J Clin Oncol. 2013 Aug 01; 31(22):2836-7. Ribas A, Hauschild A, Kefford R. PMID: 24058931.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    299. Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. Histopathology. 2013 Sep; 63(3):351-61. Jubb AM, Ribas A, Sosman JA, McArthur GA, Yan Y, Rost S, Zhao S, Koeppen H. PMID: 23802768.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    300. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. PMID: 23731854; PMCID: PMC3681569.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    301. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. PMID: 23724846; PMCID: PMC4126516.
      View in: PubMed   Mentions: 1602     Fields:    Translation:HumansCTClinical Trials
    302. BRAF-targeted therapy and immune responses to melanoma. Oncoimmunology. 2013 Jun 01; 2(6):e24462. Ngiow SF, Knight DA, Ribas A, McArthur GA, Smyth MJ. PMID: 23894707; PMCID: PMC3716742.
      View in: PubMed   Mentions: 9     Fields:    
    303. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol. 2013 Jun 10; 31(17):e283-7. Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, Andtbacka RH, Noyes RD, Shrieve DC, Grossmann KF. PMID: 23650406.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansPHPublic Health
    304. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. PMID: 23569304.
      View in: PubMed   Mentions: 179     Fields:    Translation:HumansCellsCTClinical Trials
    305. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013 Apr 04; 368(14):1365-6. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. PMID: 23550685.
      View in: PubMed   Mentions: 298     Fields:    Translation:HumansCTClinical Trials
    306. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol. 2013 Apr; 25(2):291-6. Ribas A, Wolchok JD. PMID: 23561594; PMCID: PMC3672064.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    307. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29. Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR. PMID: 23519018; PMCID: PMC3716460.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCellsCTClinical Trials
    308. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol. 2013 Apr 20; 31(12):e215-7. Klein O, Ribas A, Chmielowski B, Walker G, Clements A, Long GV, Kefford RF. PMID: 23509307.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    309. Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl. 2013 Mar 18; 52(12):3379-83. Hou S, Zhao L, Shen Q, Yu J, Ng C, Kong X, Wu D, Song M, Shi X, Xu X, OuYang WH, He R, Zhao XZ, Lee T, Brunicardi FC, Garcia MA, Ribas A, Lo RS, Tseng HR. PMID: 23436302; PMCID: PMC3807678.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCells
    310. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther. 2013 May; 21(5):1044-54. Giannoni F, Hardee CL, Wherley J, Gschweng E, Senadheera S, Kaufman ML, Chan R, Bahner I, Gersuk V, Wang X, Gjertson D, Baltimore D, Witte ON, Economou JS, Ribas A, Kohn DB. PMID: 23380815; PMCID: PMC3666644.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    311. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother. 2013 Feb; 36(2):102-11. Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J. PMID: 23377663; PMCID: PMC6410717.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    312. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ. PMID: 23454771; PMCID: PMC3582139.
      View in: PubMed   Mentions: 149     Fields:    Translation:HumansAnimalsCells
    313. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer. 2013 Jan 14; 13:17. Gentilcore G, Madonna G, Mozzillo N, Ribas A, Cossu A, Palmieri G, Ascierto PA. PMID: 23317446; PMCID: PMC3586362.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    314. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10; 31(5):616-22. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. PMID: 23295794; PMCID: PMC4878048.
      View in: PubMed   Mentions: 326     Fields:    Translation:HumansCTClinical Trials
    315. Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol. 2013 Feb 01; 31(4):499-506. McArthur GA, Ribas A. PMID: 23248252.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    316. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD. PMID: 23248257; PMCID: PMC4878037.
      View in: PubMed   Mentions: 201     Fields:    Translation:HumansCTClinical Trials
    317. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One. 2012; 7(11):e48787. Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. PMID: 23226204; PMCID: PMC3511501.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    318. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. PMID: 23171508; PMCID: PMC3543342.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    319. Cancer therapy: Tumours switch to resist. Nature. 2012 Oct 18; 490(7420):347-8. Ribas A, Tumeh PC. PMID: 23051745; PMCID: PMC3747635.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    320. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408):500-4. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. PMID: 22763439; PMCID: PMC3711467.
      View in: PubMed   Mentions: 894     Fields:    Translation:HumansCells
    321. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012 Jul 26; 487(7408):505-9. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. PMID: 22763448; PMCID: PMC3724525.
      View in: PubMed   Mentions: 608     Fields:    Translation:HumansCells
    322. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012 Sep; 2(9):791-7. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W. PMID: 22798288; PMCID: PMC3449158.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCells
    323. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. PMID: 22551296; PMCID: PMC3390271.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    324. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol. 2012 Jun 26; 8:589. Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, Mellinghoff IK, Mischel PS, Graeber TG. PMID: 22735335; PMCID: PMC3397414.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCells
    325. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A. PMID: 22693252; PMCID: PMC3422880.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansAnimalsCells
    326. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012 Jun 28; 366(26):2517-9. Ribas A. PMID: 22658126.
      View in: PubMed   Mentions: 297     Fields:    Translation:Humans
    327. Immunoediting the cancer genome--a new approach for personalized cancer therapy? Pigment Cell Melanoma Res. 2012 May; 25(3):297-8. Ribas A. PMID: 22629569.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    328. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012 Apr 19; 11:22. von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A. PMID: 22515704; PMCID: PMC3444881.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    329. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May; 2(5):414-24. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS. PMID: 22588879; PMCID: PMC3594852.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    330. Q&A: Antoni Ribas on immunotherapy progress. Cancer Discov. 2012 Apr; 2(4):293. Ribas A. PMID: 22576192.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    331. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012 May 10; 30(14):1628-34. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT, Callahan J, Hicks RJ. PMID: 22454415; PMCID: PMC5950495.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    332. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. PMID: 22395615; PMCID: PMC3530385.
      View in: PubMed   Mentions: 318     Fields:    Translation:HumansCells
    333. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23; 366(8):707-14. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. PMID: 22356324; PMCID: PMC3724515.
      View in: PubMed   Mentions: 911     Fields:    Translation:HumansCTClinical Trials
    334. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012 May 01; 18(9):2502-14. Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS. PMID: 22351686; PMCID: PMC3398738.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    335. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. PMID: 22256804; PMCID: PMC3724537.
      View in: PubMed   Mentions: 402     Fields:    Translation:HumansAnimalsCTClinical Trials
    336. Combination Therapies Building on the Efficacy of CTLA4 and BRAF Inhibitors for Metastatic Melanoma. Am Soc Clin Oncol Educ Book. 2012; 675-8. Ribas A. PMID: 24451817.
      View in: PubMed   Mentions: 1     Fields:    
    337. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. PMID: 22168571; PMCID: PMC3338100.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    338. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. PMID: 22194965; PMCID: PMC3237573.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansCells
    339. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res. 2012 Jan; 25(1):E1-11. Smalley KS, Aplin AE, Flaherty KT, Hoeller C, Bosserhoff AK, Haass NK, Bosenberg M, Ribas A, Barnhill R, Kudchadkar R, Messina JL. PMID: 22117673.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    340. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):336-41. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM. PMID: 22142824; PMCID: PMC3422891.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    341. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):E1408-16. Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z, Zack JA. PMID: 22123951; PMCID: PMC3251070.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCells
    342. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23; 480(7377):387-90. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. PMID: 22113612; PMCID: PMC3266695.
      View in: PubMed   Mentions: 717     Fields:    Translation:HumansAnimalsCells
    343. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med. 2011 Nov 13; 9:196. Ascierto PA, Marincola FM, Ribas A. PMID: 22077981; PMCID: PMC3262765.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    344. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med. 2011 Nov 07; 9:192. Konkankit VV, Kim W, Koya RC, Eskin A, Dam MA, Nelson S, Ribas A, Liau LM, Prins RM. PMID: 22060015; PMCID: PMC3229551.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    345. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol. 2012 Jan; 132(1):163-9. Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, Haskell J, Vanchinathan V, Chang PL, Tsui S, Konishi T, Comin-Anduix B, Dauphine C, Vargas HI, Economou JS, Ribas A, Bruhn KW, Craft N. PMID: 21850019; PMCID: PMC3229834.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    346. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011 Aug 01; 71(15):5067-74. Shi H, Kong X, Ribas A, Lo RS. PMID: 21803746; PMCID: PMC3149831.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCells
    347. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011 Oct; 19(10):1913-22. Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH. PMID: 21772252; PMCID: PMC3188739.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCellsCTClinical Trials
    348. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30; 364(26):2507-16. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. PMID: 21639808; PMCID: PMC3549296.
      View in: PubMed   Mentions: 3066     Fields:    Translation:HumansCTClinical Trials
    349. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011 05 24; 8(7):426-33. Ribas A, Flaherty KT. PMID: 21606968.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    350. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24; 9:76. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. PMID: 21609436; PMCID: PMC3152784.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    351. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med. 2011 Jun; 17(6):738-43. Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, Heath JR. PMID: 21602800; PMCID: PMC3681612.
      View in: PubMed   Mentions: 170     Fields:    Translation:HumansCells
    352. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A. PMID: 21558401; PMCID: PMC3117971.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCellsCTClinical Trials
    353. A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations. J Nucl Med. 2011 May; 52(5):815-21. Vu NT, Yu ZT, Comin-Anduix B, Søndergaard JN, Silverman RW, Chang CY, Ribas A, Tseng HR, Chatziioannou AF. PMID: 21536929; PMCID: PMC3270819.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    354. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32. Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM. PMID: 21439082; PMCID: PMC3078100.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    355. Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res. 2011 May 01; 17(9):2987-96. Ribas A, Weber JS, Chmielowski B, Comin-Anduix B, Lu D, Douek M, Ragavendra N, Raman S, Seja E, Rosario D, Miles S, Diamond DC, Qiu Z, Obrocea M, Bot A. PMID: 21385924.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    356. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011 Apr 01; 71(7):2750-60. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS. PMID: 21317224; PMCID: PMC3070772.
      View in: PubMed   Mentions: 259     Fields:    Translation:HumansCells
    357. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8. Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas A. PMID: 21169256; PMCID: PMC3057460.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCells
    358. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. PMID: 21107323; PMCID: PMC3143360.
      View in: PubMed   Mentions: 1078     Fields:    Translation:HumansCells
    359. Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling. Future Oncol. 2010 Nov; 6(11):1671-3. Ribas A, Koya RC. PMID: 21142653.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    360. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol. 2011 Feb; 131(2):453-60. Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A. PMID: 20944646.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    361. CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother. 2010 Oct; 33(8):810-6. Kalbasi A, Fonsatti E, Natali PG, Altomonte M, Bertocci E, Cutaia O, Calabrò L, Chiou M, Tap W, Chmielowski B, Maio M, Ribas A. PMID: 20842056.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    362. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother. 2010 Oct; 33(8):759-68. Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, Ribas A. PMID: 20842061; PMCID: PMC3114626.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    363. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol. 2010 Oct; 37(5):450-4. Ribas A. PMID: 21074059.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    364. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010 Sep 30; 467(7315):596-9. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. PMID: 20823850; PMCID: PMC2948082.
      View in: PubMed   Mentions: 774     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    365. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010 Sep 27; 8:89. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. PMID: 20875102; PMCID: PMC2954849.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    366. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010 Sep 15; 5(9):e12711. Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, Koya RC, Ribas A. PMID: 20856802; PMCID: PMC2939876.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    367. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 Aug 26; 363(9):809-19. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. PMID: 20818844; PMCID: PMC3724529.
      View in: PubMed   Mentions: 1492     Fields:    Translation:HumansCTClinical Trials
    368. Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7. Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, Kirkwood JM, Leachman S, Messina J, O'Day S, Ribas A, Sondak V. PMID: 20718940.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    369. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug 01; 116(15):3683-91. Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E. PMID: 20564083.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    370. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One. 2010 Jul 22; 5(7):e11726. Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA. PMID: 20668510; PMCID: PMC2908680.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansAnimalsCells
    371. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14286-91. Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A. PMID: 20624956; PMCID: PMC2922609.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    372. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother. 2010 Jul-Aug; 33(6):557-69. Agarwala SS, Ribas A. PMID: 20551840.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    373. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010 Sep; 136(3):338-47. Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B, UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity. PMID: 20547105; PMCID: PMC2917536.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    374. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010 Apr 20; 8:39. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A. PMID: 20406486; PMCID: PMC2876068.
      View in: PubMed   Mentions: 121     Fields:    Translation:HumansAnimalsCells
    375. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010 Apr 15; 464(7291):1067-70. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. PMID: 20305636; PMCID: PMC2855406.
      View in: PubMed   Mentions: 768     Fields:    Translation:Humans
    376. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010 Mar; 51(3):340-6. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. PMID: 20150263.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    377. Immune rejection in a humanized model of murine prostate cancer. Anticancer Res. 2010 Feb; 30(2):409-14. Schaue D, Koya RC, Liao YP, Ribas A, McBride WH. PMID: 20332447.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    378. Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma. Pigment Cell Melanoma Res. 2010 Apr; 23(2):288-9. Baltimore D, Witte ON, Yang L, Economou J, Ribas A. PMID: 20067554.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    379. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010 Jan 01; 116(1):155-63. Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R. PMID: 19877111.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    380. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009 Dec 01; 15(23):7116-8. Ribas A, Chmielowski B, Glaspy JA. PMID: 19934296.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    381. Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin Dermatol. 2009 Nov-Dec; 27(6):603-13. Ray S, Chhabra A, Mehrotra S, Chakraborty NG, Ribas A, Economou J, Mukherji B. PMID: 19880048.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsPHPublic Health
    382. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009 Nov 15; 69(22):8693-9. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, Yang MY, Mok S, Garban HJ, Craft N, Economou JS, Marincola FM, Wang E, Ribas A. PMID: 19861533; PMCID: PMC2779578.
      View in: PubMed   Mentions: 87     Fields:    Translation:AnimalsCells
    383. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 01; 15(19):6267-76. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. PMID: 19789309; PMCID: PMC2765061.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCellsCTClinical Trials
    384. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med. 2009 Jul 29; 7:68. Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA. PMID: 19640287; PMCID: PMC2724499.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    385. Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc. 2009 Jul 22; 131(28):9695-703. Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, Comin-Anduix B, Hadrup SR, Bailey RC, Witte ON, Schumacher TN, Ribas A, Heath JR. PMID: 19552409; PMCID: PMC2720314.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    386. Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res. 2009 Oct; 22(5):532-43. Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK. PMID: 19659612.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    387. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med. 2009 Jun 17; 7:45. Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM. PMID: 19534815; PMCID: PMC2724494.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    388. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009 May 20; 7:35. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A. PMID: 19457253; PMCID: PMC2697137.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCellsCTClinical Trials
    389. Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? J Clin Oncol. 2009 Jun 20; 27(18):2896-7. Glaspy J, Ribas A, Chmielowski B. PMID: 19433677.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    390. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009 Jun; 55(6):1342-3. Bellmunt J, Ribas A. PMID: 19201525.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    391. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009 Jan 13; 6(1):e10. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG. PMID: 19143470; PMCID: PMC2621261.
      View in: PubMed   Mentions: 201     Fields:    Translation:HumansAnimalsCells
    392. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. PMID: 19139427.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCTClinical Trials
    393. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009 Jan 01; 15(1):390-9. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. PMID: 19118070.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    394. A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med. 2008 Dec 23; 6:81. Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM. PMID: 19105846; PMCID: PMC2630944.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    395. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol. 2009 Feb; 21(2):155-65. Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A, Phelps ME, Witte ON. PMID: 19106231; PMCID: PMC2638874.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    396. Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother. 2009 May; 58(5):699-708. Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A. PMID: 18807035.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    397. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res. 2008 Aug 01; 14(15):4883-90. Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, Debucquoy A, Haustermans K, McBride WH. PMID: 18676762; PMCID: PMC2748652.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCells
    398. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res. 2008 Jul 15; 14(14):4385-91. Begley J, Ribas A. PMID: 18628452.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    399. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol. 2008 Jul 15; 181(2):1063-70. Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, Mukherji B. PMID: 18606658; PMCID: PMC2715965.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    400. PET imaging of cancer immunotherapy. J Nucl Med. 2008 Jun; 49(6):865-8. Tumeh PC, Radu CG, Ribas A. PMID: 18511842.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    401. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 01; 6:22. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. PMID: 18452610; PMCID: PMC2412852.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCellsCTClinical Trials
    402. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008 Apr; 31(3):294-309. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. PMID: 18317358; PMCID: PMC3651040.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCellsCTClinical Trials
    403. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother. 2008 Sep; 57(9):1279-89. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, Yang MY, Lin MS, Shelly S, Witte ON, Ribas A, Liau LM. PMID: 18253732; PMCID: PMC2614264.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    404. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist. 2008; 13 Suppl 4:10-5. Ribas A. PMID: 19001146.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    405. Therapeutic cancer vaccines. Surg Oncol Clin N Am. 2007 Oct; 16(4):819-31, ix. Morris LF, Ribas A. PMID: 18022546.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    406. Anti-CTLA4 Antibody Clinical Trials in Melanoma. Update Cancer Ther. 2007 Sep; 2(3):133-139. Ribas A. PMID: 19543441; PMCID: PMC2699286.
      View in: PubMed   Mentions: 20  
    407. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist. 2007 Jul; 12(7):873-83. Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, Canniff PC, Sharma A, Gomez-Navarro J. PMID: 17673618.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    408. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother. 2007 Dec; 56(12):1931-43. Butterfield LH, Ribas A, Potter DM, Economou JS. PMID: 17522860.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    409. Metastatic melanoma to the kidney presenting with renal vein tumor thrombus. Urology. 2007 May; 69(5):982.e7-9. Klatte T, Rao JY, Ribas A, Pantuck AJ. PMID: 17482952.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    410. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol. 2007 Jun; 143(6):958-969. Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A. PMID: 17434437.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    411. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther. 2007 May; 15(5):971-80. Koya RC, Kimura T, Ribas A, Rozengurt N, Lawson GW, Faure-Kumar E, Wang HJ, Herschman H, Kasahara N, Stripecke R. PMID: 17375074.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    412. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol. 2006 Dec 15; 177(12):8448-55. Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A. PMID: 17142742.
      View in: PubMed   Mentions: 30     Fields:    Translation:AnimalsCells
    413. Update on immunotherapy for melanoma. J Natl Compr Canc Netw. 2006 Aug; 4(7):687-94. Ribas A. PMID: 16884670.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    414. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006 May 01; 12(9):2817-25. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. PMID: 16675576.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCellsCTClinical Trials
    415. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol. 2006 Apr 15; 176(8):4757-65. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A. PMID: 16585569.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCellsPHPublic Health
    416. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Mol Immunol. 2006 Feb; 43(6):667-76. Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet ML. PMID: 15908002.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCellsPHPublic Health
    417. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res. 2006 Jan 01; 12(1):107-16. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A. PMID: 16397031.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    418. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther. 2005 Dec; 5(6):619-28. Ribas A. PMID: 16457651.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    419. Clinical trials with tumor antigen genetically modified dendritic cells. Semin Oncol. 2005 Dec; 32(6):556-62. Ribas A. PMID: 16338421.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    420. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10; 23(35):8968-77. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. PMID: 16204013.
      View in: PubMed   Mentions: 182     Fields:    Translation:HumansCellsCTClinical Trials
    421. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 2005 Aug 15; 65(16):7194-204. Ali S, King GD, Curtin JF, Candolfi M, Xiong W, Liu C, Puntel M, Cheng Q, Prieto J, Ribas A, Kupiec-Weglinski J, van Rooijen N, Lassmann H, Lowenstein PR, Castro MG. PMID: 16103070; PMCID: PMC1242178.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCells
    422. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother. 2006 Jun; 55(6):663-71. Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy JA, Economou JS. PMID: 16133107.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    423. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther. 2005 Jun; 12(6):516-27. Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A. PMID: 15775996.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    424. Role